Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 56Breast Neoplasms 50Ovarian Neoplasms 33Triple Negative Breast Neoplasms 27Endometrial Neoplasms 25Lung Neoplasms 24Neoplasm Metastasis 23Fallopian Tube Neoplasms 23Squamous Cell Carcinoma of Head and Neck 19Parkinson Disease 4, Autosomal Dominant Lewy Body 18Neoplasms 14Esophageal Squamous Cell Carcinoma 12Esophageal Neoplasms 12Carcinoma, Ovarian Epithelial 9Stomach Neoplasms 8Head and Neck Neoplasms 8Colorectal Neoplasms 8Carcinoma 8Adenocarcinoma Of Esophagus 7Adenocarcinoma 7Peritoneal Neoplasms 6Uterine Cervical Neoplasms 5Melanoma 5Small Cell Lung Carcinoma 4Oropharyngeal Neoplasms 4Cholangiocarcinoma 4Carcinoma, Transitional Cell 4Uterine Neoplasms 3Recurrence 3Pancreatic Neoplasms 3

Interventions

durvalumab 8Bevacizumab 7tremelimumab 4lenvatinib 3atezolizumab 3Nivolumab 3Ipilimumab 3fludarabine 2Magnetic Resonance Imaging 2Hepatectomy 2Gemcitabine 2Cyclophosphamide 2Cisplatin 2trastuzumab deruxtecan 1toripalimab 1ropidoxuridine 1poly ICLC 1pembrolizumab 1brodalumab 1Whole Genome Sequencing 1Standard of Care 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radionuclide Imaging 1Pluvicto 1Platinum 1Paclitaxel 1Laparoscopy 1Immunotherapy, Adoptive 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × Paclitaxel × 90 days × Clear all
NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Eisai Inc.

Phase 1/2 Active not recruiting
301 enrolled
GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡